Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Cancer × cabiralizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Head and Neck Neoplasms 1 Glioma 1 Advanced Malignancies 1 Advanced Cancer 1

Interventions

Nivolumab 8 Paclitaxel 6 Sirolimus 5 Bevacizumab 5 temsirolimus 4 Pemetrexed 4 Ipilimumab 4 Docetaxel 4 Carboplatin 4 ARRY-334543 4 Gemcitabine 3 Erlotinib Hydrochloride 3 olaparib 2 linrodostat 2 apatinib 2 anlotinib 2 abemaciclib 2 Vorinostat 2 Sunitinib 2 Magnetic Resonance Spectroscopy 2 Irinotecan 2 Everolimus 2 Doxorubicin 2 Dasatinib 2 Chlorogenic Acid 2 Cetuximab 2 6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2 vorolanib 1 vistusertib 1 trametinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03335540 2022-09-26

ADVISE

Bristol-Myers Squibb

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡